/ESLA
ESLA Stock - Estrella Immunopharma, Inc.
Healthcare|BiotechnologyNASDAQ
$1.69+6.96%
+$0.11 (+6.96%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.99
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.86
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ESLA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.67 – $1.71
TARGET (TP)$1.94
STOP LOSS$1.55
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.53
52W High$3.15
52W Low$0.73
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-8,845,941 | $-7,310,098 | $-1,569,530 | $-1,685,347 | $-733,693 |
| Net Income | $-8,847,629 | $-7,311,723 | $-996,104 | $-1,685,347 | $-733,693 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.25 | $-0.21 | $-0.17 | $-0.29 | $-0.02 |
Company Overview
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ESLABeat Rate
75%
Last 4 quarters
Avg Surprise
+9.4%
EPS vs Estimate
Beats / Misses
3/1
Last 12 quarters
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
+76.1%
$-0.03vs$-0.12
Q2 25
+45.5%
$-0.06vs$-0.11
Q3 25
-114.3%
$-0.15vs$-0.07
Q4 25
+30.3%
$-0.13vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | $-0.19 | $-0.13 | +30.3% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.07 | $-0.15 | -114.3% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q1 2025 | Feb 15, 2025 | $-0.12 | $-0.03 | +76.1% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | — | $-0.09 | — | — |
Q3 2024 | Sep 27, 2024 | — | $-0.13 | — | — |
Q2 2024 | May 14, 2024 | — | $-0.01 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-0.03 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-1.78 | — | — |
Q2 2023 | Jun 29, 2023 | — | $-0.03 | — | — |
Q1 2023 | Mar 30, 2023 | — | $-0.03 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1.18 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.06 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.03 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.03 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.02 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Latest News
Estrella Immunopharma Recommended By Independent Data Safety Monitoring Board To Advance STARLIGHT-1 Study To Phase II After Review Of Safety Data
📈 PositiveBenzinga•Dec 4, 2025, 01:04 PM
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
📈 PositiveBenzinga•Nov 3, 2025, 04:23 PM
Estrella Immunopharma Completes Second Dose Cohort In STARLIGHT-1 Phase I/II Clinical Trial Of EB103
📈 PositiveBenzinga•Nov 3, 2025, 01:08 PM
Estrella Immunopharma Regains Nasdaq Compliance
📈 PositiveBenzinga•Oct 6, 2025, 12:13 PM
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up
📈 PositiveSeeking Alpha•Jun 3, 2025, 12:22 PM
Frequently Asked Questions about ESLA
What is ESLA's current stock price?
Estrella Immunopharma, Inc. (ESLA) is currently trading at $1.69 per share. The stock has moved +6.96% today.
What is the analyst price target for ESLA?
No analyst price targets are currently available for this stock.
What sector is Estrella Immunopharma, Inc. in?
Estrella Immunopharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ESLA's market cap?
Estrella Immunopharma, Inc. has a market capitalization of $0.06 billion, making it a small-cap company.
Does ESLA pay dividends?
No, Estrella Immunopharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANEB
Anebulo Pharmaceuticals, Inc.
$2.17
Mkt Cap: $0.1B
ATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
EXOZ
eXoZymes, Inc.
$12.30
Mkt Cap: $0.1B
GLSI
Greenwich LifeSciences, Inc.
$13.01
Mkt Cap: $0.2B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
ONCY
Oncolytics Biotech Inc.
$1.01
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
TIL
Instil Bio, Inc.
$11.27
Mkt Cap: $0.1B
TLSA
Tiziana Life Sciences Ltd
$1.52
Mkt Cap: $0.1B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
Explore stocks similar to ESLA for comparison